                         SEQUENCE LISTING

<110>  SEATTLE GENETICS, INC.
 
<120>  ANTI-NTB-A ANTIBODIES AND RELATED COMPOSITIONS AND METHODS

<130>  NTBA-00111PC

<150>  US 61/745,239
<151>  2012-12-21

<160>  16    

<170>  PatentIn version 3.5

<210>  1
<211>  135
<212>  PRT
<213>  Artificial

<220>
<223>  Anti-NTB-A mAb Variable Region 11A1 (VH)

<400>  1

Met Lys Cys Ser Trp Ile Ile Phe Phe Leu Met Ala Val Val Thr Gly 
1               5                   10                  15      


Val Asn Ser Glu Val His Leu Gln Gln Ser Gly Ala Glu Leu Val Lys 
            20                  25                  30          


Pro Gly Ala Ser Val Lys Leu Ser Cys Thr Ala Ser Gly Phe Asn Ile 
        35                  40                  45              


Lys Asp Tyr Tyr Val His Trp Val Lys Gln Arg Thr Glu Gln Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Lys Ile Asp Pro Glu Asp Gly Glu Ile Lys Tyr Ala 
65                  70                  75                  80  


Pro Lys Phe Gln Gly Glu Ala Thr Ile Thr Ala Asp Thr Ser Ser Asn 
                85                  90                  95      


Thr Ala Tyr Leu Gln Leu Ser Ser Leu Thr Ser Glu Asp Thr Ala Val 
            100                 105                 110         


Tyr Tyr Cys Ala Arg Tyr Ser Thr Tyr Phe Asp Tyr Trp Gly Gln Gly 
        115                 120                 125             


Thr Thr Leu Thr Val Ser Ser 
    130                 135 


<210>  2
<211>  140
<212>  PRT
<213>  Artificial

<220>
<223>  Anti-NTB-A mAb Variable Region 11A1 (VL)

<400>  2

Met Glu Ser Asn Thr Leu Leu Leu Trp Val Leu Leu Leu Trp Val Pro 
1               5                   10                  15      


Gly Ser Thr Gly Asp Ile Val Leu Thr Gln Ser Pro Ala Ser Leu Ala 
            20                  25                  30          


Val Ser Leu Gly Gln Lys Ala Thr Ile Ser Cys Lys Ala Ser Lys Lys 
        35                  40                  45              


Val Thr Ile Phe Gly Ser Ile Ser Ala Leu His Trp Tyr Gln Gln Lys 
    50                  55                  60                  


Pro Gly Gln Pro Pro Lys Leu Ile Tyr Asn Gly Ala Lys Leu Glu Ser 
65                  70                  75                  80  


Gly Val Ser Ala Arg Phe Ser Asp Ser Gly Ser Gln Asn Arg Ser Gln 
                85                  90                  95      


Phe Gly Asn Gln Leu Ser Leu Thr Leu Thr Ile Asp Pro Val Glu Ala 
            100                 105                 110         


Asp Asp Ala Ala Thr Tyr Tyr Cys Leu Gln Asn Lys Glu Val Pro Tyr 
        115                 120                 125             


Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
    130                 135                 140 


<210>  3
<211>  137
<212>  PRT
<213>  Artificial

<220>
<223>  Anti-NTB-A mAb Variable Region 26B7 (VH)

<400>  3

Met Gly Trp Ser Tyr Ile Ile Leu Phe Leu Val Ala Thr Ala Thr Gly 
1               5                   10                  15      


Val His Ser Gln Val Gln Leu Leu Gln Pro Gly Ala Glu Val Val Lys 
            20                  25                  30          


Pro Gly Thr Ser Val Lys Leu Ser Cys Lys Ala Ser Gly Tyr Asn Phe 
        35                  40                  45              


Thr Ile Tyr Trp Ile Asn Trp Val Lys Leu Arg Pro Gly Gln Gly Leu 
    50                  55                  60                  


Glu Trp Ile Gly Asp Ile His Pro Gly Arg Gly Asn Thr Asn Leu Asn 
65                  70                  75                  80  


Glu Lys Phe Lys Thr Lys Ala Thr Leu Thr Val Asp Thr Ser Ser Ser 
                85                  90                  95      


Thr Ala Tyr Met Gln Leu Asn Ser Leu Ala Phe Glu Asp Ser Ala Leu 
            100                 105                 110         


Tyr Tyr Cys Ala Arg Glu Asp Glu Asp Trp Tyr Phe Asp Val Trp Gly 
        115                 120                 125             


Ala Gly Thr Thr Val Thr Val Ser Ser 
    130                 135         


<210>  4
<211>  128
<212>  PRT
<213>  Artificial

<220>
<223>  Anti-NTB-A mAb Variable Region 26B7 (VL)

<400>  4

Met Lys Leu Leu Ala Glu Leu Leu Gly Leu Leu Leu Phe Cys Phe Ser 
1               5                   10                  15      


Gly Val Arg Cys Asp Ile Gln Met Asn Gln Ser Pro Ser Ser Leu Ser 
            20                  25                  30          


Ala Ser Leu Gly Asp Thr Ile Thr Ile Thr Cys Arg Ala Ser Gln Gly 
        35                  40                  45              


Ile Ser Ile Trp Phe Asn Trp Tyr Gln Gln Lys Ser Gly Asn Ile Pro 
    50                  55                  60                  


Lys Leu Leu Ile Tyr Lys Thr Ser Asn Leu His Thr Gly Val Pro Pro 
65                  70                  75                  80  


Arg Phe Ser Gly Ser Gly Ser Gly Thr Asp Phe Thr Leu Thr Ile Ser 
                85                  90                  95      


Ser Leu Gln Pro Glu Asp Ile Ala Thr Tyr Tyr Cys Leu Gln Ser Gln 
            100                 105                 110         


Ser Tyr Pro Tyr Thr Phe Gly Gly Gly Thr Lys Leu Glu Ile Lys Arg 
        115                 120                 125             


<210>  5
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 11A1

<400>  5

Asp Tyr Tyr Val His 
1               5   


<210>  6
<211>  17
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 11A1

<400>  6

Lys Ile Asp Pro Glu Asp Gly Glu Ile Lys Tyr Ala Pro Lys Phe Gln 
1               5                   10                  15      


Gly 
    


<210>  7
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 11A1

<400>  7

Tyr Ser Thr Tyr Phe Asp Tyr 
1               5           


<210>  8
<211>  16
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 11A1

<400>  8

Lys Ala Ser Lys Lys Val Thr Ile Phe Gly Ser Ile Ser Ala Leu His 
1               5                   10                  15      


<210>  9
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 11A1

<400>  9

Asn Gly Ala Lys Leu Glu Ser 
1               5           


<210>  10
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 11A1

<400>  10

Leu Gln Asn Lys Glu Val Pro Tyr Thr 
1               5                   


<210>  11
<211>  5
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 26B7

<400>  11

Ile Tyr Trp Ile Asn 
1               5   


<210>  12
<211>  17
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 26B7

<400>  12

Asp Ile His Pro Gly Arg Gly Asn Thr Asn Leu Asn Glu Lys Phe Lys 
1               5                   10                  15      


Thr 
    


<210>  13
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 26B7

<400>  13

Glu Asp Glu Asp Trp Tyr Phe Asp Val 
1               5                   


<210>  14
<211>  11
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 26B7

<400>  14

Arg Ala Ser Gln Gly Ile Ser Ile Trp Phe Asn 
1               5                   10      


<210>  15
<211>  7
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 26B7

<400>  15

Lys Thr Ser Asn Leu His Thr 
1               5           


<210>  16
<211>  9
<212>  PRT
<213>  Artificial

<220>
<223>  CDR Sequence for Anti-NTB-A Antibody VH and VL Domain 26B7

<400>  16

Leu Gln Ser Gln Ser Tyr Pro Tyr Thr 
1               5                   


